PRA Health Sciences Inc (PRAH)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:PRA Health Sciences Inc (PRAH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014324
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PRA Health Sciences Inc (PRA) is a contract research organization(CRO) which provides clinical development services. The company offers services such as phase I-IV study management, and embedded and functional outsourcing services. It offers solutions in bioanalytical laboratories, biometrics, clinical pharmacology, strategic solutions, post-marketing research, clinical diagnostics, and safety and risk management. PRA spans its expertise in the therapeutic areas of biosimilars, oncology, hematology, respiratory, rare diseases, neurology, infectious diseases, cardio-metabolic and immunology. It caters to pharmaceutical and biotechnology industries. The company has presence in the US, Hong Kong, Russia, India, France, Italy, China, Japan, South Africa, Israel and Colombia among others. PRA is headquartered in Raleigh, North Carolina, the US.

PRA Health Sciences Inc (PRAH) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
PRA Health Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
PRA Health Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
PRA Health Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
PRA Health Sciences Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
PRA Health Sciences Inc, Medical Devices Deals, 2011 to YTD 2017 10
PRA Health Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
PRA Health Sciences Inc, Pharmaceuticals & Healthcare, Deal Details 13
Private Equity 13
KKR Completes Acquisition Of PRA International From Genstar Capital 13
KKR Completes Acquisition Of ReSearch Pharma Services From Warburg Pincus 15
Warburg Pincus Completes Acquisition Of ReSearch Pharma Services 16
Partnerships 18
Care Innovations Enters into Partnership with PRA Health Sciences 18
Delmar Pharma Enters into Agreement with PRA Health Sciences 19
PRA Health Sciences and Takeda Pharma Form Joint Venture 20
PRA Health Sciences Enters into Agreement with Takeda Pharma 21
PRA Health Sciences Enters into Agreement with Alliance for Multispecialty Research 22
ReSearch Pharma Forms Joint Venture With Asklep 23
WuXi PharmaTech To Form Joint Venture With PRA International 24
Equity Offering 25
PRA Health Sciences Prices Public Offering of Shares 25
PRA Health Sciences Raises USD416.3 Million in Public Offering of Shares 27
PRA Health Sciences Raises USD234 Million in Public Offering of Shares 29
PRA Health Sciences Raises USD211.3 Million in Public Offering of Shares 30
PRA Health Sciences Completes IPO for USD351.4 Million 31
PRA Files Draft Registration Statement For IPO 33
Acquisition 34
PRA International Acquires CRI Lifetree, Specialized Research Organization 34
PRA Health Sciences Acquires ReSearch Pharma 35
PRA International Acquires ClinStar, Clinical Research Organization 36
PRA International Acquires Kinship Technologies 37
PRA Health Sciences Inc – Key Competitors 38
PRA Health Sciences Inc – Key Employees 39
PRA Health Sciences Inc – Locations And Subsidiaries 40
Head Office 40
Other Locations & Subsidiaries 40
Joint Venture 42
Recent Developments 43
Financial Announcements 43
Oct 25, 2017: PRA Health Sciences Reports Third Quarter 2017 Results and Updates Full Year 2017 Guidance 43
Aug 07, 2017: PRA Health Sciences Reports Second Quarter 2017 Results and Updates Full Year 2017 Guidance 45
Apr 25, 2017: PRA Health Sciences Reports First Quarter 2017 Results 47
Feb 22, 2017: PRA Health Sciences Reports Fourth Quarter and Full Year 2016 Results and Provides Q1 and Full Year 2017 Guidance 49
Nov 02, 2016: PRA Health Sciences Reports Third Quarter 2016 Results and Updates 2016 Guidance 51
Jul 28, 2016: PRA Health Sciences Reports Second Quarter 2016 Results 53
Apr 27, 2016: PRA Health Sciences Reports First Quarter 2016 Results and Updates 2016 Guidance 54
Feb 24, 2016: PRA Health Sciences Reports Fourth Quarter and Full Year 2015 Results and Provides 2016 Guidance 55
Corporate Communications 57
Aug 14, 2017: PRA Health Sciences Announces Appointment of New Director 57
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
PRA Health Sciences Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
PRA Health Sciences Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
PRA Health Sciences Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
PRA Health Sciences Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
PRA Health Sciences Inc, Deals By Therapy Area, 2011 to YTD 2017 9
PRA Health Sciences Inc, Medical Devices Deals, 2011 to YTD 2017 10
PRA Health Sciences Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
KKR Completes Acquisition Of PRA International From Genstar Capital 13
KKR Completes Acquisition Of ReSearch Pharma Services From Warburg Pincus 15
Warburg Pincus Completes Acquisition Of ReSearch Pharma Services 16
Care Innovations Enters into Partnership with PRA Health Sciences 18
Delmar Pharma Enters into Agreement with PRA Health Sciences 19
PRA Health Sciences and Takeda Pharma Form Joint Venture 20
PRA Health Sciences Enters into Agreement with Takeda Pharma 21
PRA Health Sciences Enters into Agreement with Alliance for Multispecialty Research 22
ReSearch Pharma Forms Joint Venture With Asklep 23
WuXi PharmaTech To Form Joint Venture With PRA International 24
PRA Health Sciences Prices Public Offering of Shares 25
PRA Health Sciences Raises USD416.3 Million in Public Offering of Shares 27
PRA Health Sciences Raises USD234 Million in Public Offering of Shares 29
PRA Health Sciences Raises USD211.3 Million in Public Offering of Shares 30
PRA Health Sciences Completes IPO for USD351.4 Million 31
PRA Files Draft Registration Statement For IPO 33
PRA International Acquires CRI Lifetree, Specialized Research Organization 34
PRA Health Sciences Acquires ReSearch Pharma 35
PRA International Acquires ClinStar, Clinical Research Organization 36
PRA International Acquires Kinship Technologies 37
PRA Health Sciences Inc, Key Competitors 38
PRA Health Sciences Inc, Key Employees 39
PRA Health Sciences Inc, Other Locations 40
PRA Health Sciences Inc, Subsidiaries 41
PRA Health Sciences Inc, Joint Venture 42

★海外企業調査レポート[PRA Health Sciences Inc (PRAH)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Specialised Therapeutics Australia Pty Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Specialised Therapeutics Australia Pty Ltd (STA) is a biopharmaceutical company that develops and commercializes therapies and technologies for unmet medical needs. The company’s product portfolio includes abraxane, gliolan, oncotype dx, iclusig, oncotype dx prostate and aloxi. Its pipeline …
  • PRA Health Sciences Inc (PRAH):企業の財務・戦略的SWOT分析
    Summary PRA Health Sciences Inc (PRA) is a contract research organization (CRO) which provides outsourced clinical development and data solution services. The company offers asset valuation, regulatory and drug development consulting, risk-based monitoring, site identification and selection, medical …
  • Rad Source Technologies Inc:企業の戦略的SWOT分析
    Rad Source Technologies Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major product …
  • The Kiyo Bank Ltd:企業の戦略・SWOT・財務分析
    The Kiyo Bank Ltd - Strategy, SWOT and Corporate Finance Report Summary The Kiyo Bank Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • E.ON SE (EOAN):企業の財務・戦略的SWOT分析
    E.ON SE (EOAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Tessa Therapeutics Pte Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Tessa Therapeutics Pte Ltd (Tessa Therapeutics) is a clinical-stage biotechnology company that develops and commercializes cancer immunotherapies that redirect the body’s powerful anti-viral immune response to identify and exterminate cancer cells. The company provides products for various c …
  • Dolby Laboratories Inc (DLB):企業の財務・戦略的SWOT分析
    Dolby Laboratories Inc (DLB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Bionik Laboratories Corp (BNKL):企業の製品パイプライン分析2018
    Summary Bionik Laboratories Corp (Bionik) is a medical device company that designs and develops transformational technologies, prosthetics and assisted robotic products and solutions. The company provides rehabilitation technology that senses patient movements and limitations. It provides lower body …
  • Eguana Technologies Inc. (EGT):企業の財務・戦略的SWOT分析
    Eguana Technologies Inc. (EGT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Ventana Medical Systems Inc-医療機器分野:企業M&A・提携分析
    Summary Ventana Medical Systems Inc (VMS), a subsidiary of F. Hoffmann-La Roche Ltd is a manufacturer of tissue-based diagnostic solutions for healthcare market. The company develops cancer diagnostic solutions for breast pathology, cervical diagnostics, colorectal pathology, special stains, lung pa …
  • Drugs for Neglected Diseases initiative-製薬・医療分野:企業M&A・提携分析
    Summary Drugs for Neglected Diseases initiative (DNDi) is a research center that discovers and develops new drugs. The center develops therapeutics for the treatment of various diseases. It offers treatments which include ASAQ, ASMQ, NECT, SSG&PM and pediatric benznidazole. DNDi also offers products …
  • BCD Travel Services B.V.:企業の戦略・SWOT・財務情報
    BCD Travel Services B.V. - Strategy, SWOT and Corporate Finance Report Summary BCD Travel Services B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Inditex SA (ITX):企業の財務・戦略的SWOT分析
    Inditex SA (ITX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Covance Inc:企業の戦略的SWOT分析
    Covance Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • McGill University:製薬・医療:M&Aディール及び事業提携情報
    Summary McGill University (McGill) is a medical-doctoral university. The institute offers undergraduate, graduate, post-graduate courses besides research programs. It provides academic courses across various disciplines including agricultural and environmental sciences, arts, dentistry, education, e …
  • IMEXHS Ltd (IME):企業の財務・戦略的SWOT分析
    IMEXHS Ltd (IME) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Nufarm Limited (NUF):企業の財務・戦略的SWOT分析
    Nufarm Limited (NUF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Cinemark Holdings Inc (CNK):企業の財務・戦略的SWOT分析
    Cinemark Holdings Inc (CNK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Congenica Ltd-医療機器分野:企業M&A・提携分析
    Summary Congenica Ltd (Congenica) is a biotechnology company that offers research and experimental development on biotechnology. The company’s technology SAPIENTIA, is used to personalize patient care through accurate diagnoses, support clinical trials, and drug development. It offers services such …
  • Genalyte Inc:製品パイプライン分析
    Summary Genalyte Inc (Genalyte) is a healthcare service provider that develops cancer biomarker panels and testing platforms for screening. The company provides technologies such as the Maverick Detection System and Silicon Photonics Biosensor technology. Its Maverick Detection System quantifies the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆